Hanson Wade’s Post

As per DelveInsight analysis, the Endometrial Cancer market is expected to grow positively in the upcoming years owing to the active participation of the major pharma and biotech giants such as AstraZeneca, Karyopharm Therapeutics Inc., Evergreen Therapeutics, Inc., ImmunoGen, Inc., Merck, TESARO, Inc., Abbott, Roche, Chimerix, Inc., Bayer, ImmunoGen, Inc., Incyte, Eli Lilly and Company, Gilead Sciences, Genentech, and others in the therapeutics segment. Learn more about the major trends and developments driving the Endometrial Cancer market growth: https://lnkd.in/gp8-nmbt #lifesciences #marketresearch #marketanalysis #healthcare #markettrends #health #medical #marketforecast #markettrends #consulting #healthcareconsulting #marketoutlook #endometrialcancer

🌟 Unlock the Latest Insights into the c-MET Non-Small Cell Lung Cancer Market! 🌟 DelveInsight Business Research LLP's comprehensive market report delves into the evolving landscape of c-MET #NSCLC, exploring cutting-edge therapeutics, ongoing clinical trials, and emerging trends that are shaping the future of this space. The leading #CMETNSCLCCompanies are mentioned below:- 1. AbbVie 2. Janssen Inc. Research & Development 3. Beijing Pearl Biotechnology Limited Liability Company 4. Novartis 🔍 Key c-MET Non-Small Cell Lung Cancer Market Report Highlights: ✔ Market Dynamics ✔ #NSCLCTreatment Landscape ✔ Competitive Insights ✔ Growth Opportunities Stay ahead in understanding the advancements driving innovation in the c-MET #NSCLCMarket. 📖 Discover More @ https://lnkd.in/eWqnBmTH #LungCancer #NSCLC #cMET #DelveInsight #MarketReport #PharmaInsights #OncologyMarket #BiotechInnovation

Breaking ground in Oncology: Europe's Next Chapter 🌍💡 In an unprecedented move, leading pharmaceutical giants are gearing up for a series of large-scale clinical trials in oncology across Europe. With innovative therapies on the horizon, the focus is sharpening on the critical role of staffing to ensure these trials succeed. Groundbreaking research promises not just hope, but real change. From targeted therapies to immunotherapies, these trials could redefine cancer treatment as we know it. As each phase demands precision and expert knowledge, the need for top-tier clinical researchers, data analysts, and medical professionals is at its peak. Europe stands at the forefront of this endeavour, and it's our shared mission to see it thrive. We're talking cutting-edge science meeting top talent to transform lives. Join the conversation - what's your take on Europe's potential to lead the next wave of oncology breakthroughs? #OncologyInnovation #ClinicalTrials #PharmaCareers #HRS #Science

Precision Oncology is a Growing Market … More Room for Blockbuster Sales 👉 Precision Oncology is a rapidly growing market with the potential to transform clinical practice. Advancements in science and medicine have highlighted that cancer is a disease of the genome, not just a specific anatomical location 👉  Moving treatments earlier in therapy could significantly enhance overall survival efficacy, a key driver in the evolution of precision oncology. Recent M&A activity in the field, such as Merck's acquisition of Harpoon Therapeutics and J&J's purchase of Ambrx Biopharma, emphasizes the industry's dynamism 👉 Despite its promising future, precision oncology encounters challenges in regulatory, reimbursement, and intellectual property domains. Structural hurdles also contribute to a competitive landscape. Stay tuned for more insights into this groundbreaking sector #PrecisionOncology #MedicalAdvancements #HealthcareIndustry #ClinicalInnovations #precisiononcology #targetedtherapy #cancertreatment #competitiveintelligence #marketintelligence #perspectives #eosintelligence #leadership #lifesciences #pharmaceuticals #management #consulting #marketing #marketresearch #oncologydrugs #oncology #biotech --------------------------------------------------------------------------------- Write to me at bhabesh.panigrahi@eos-intelligence to schedule a no-obligation consultation for a winning precision oncology treatment strategy

Join Consilium for our first post-summer event on Thursday, 5th September! ❓ Do we need Phase 3 trials in oncology? 📅 Thursday 5th September, 5pm London Time 🎫 Sign up here: https://lnkd.in/djYW5eQu Waste in cancer research has been disappointing to many whilst allowing significant capitalisation for pharmaceutical industry. Many improvements have been made and many more are yet to come. How should cancer research evolve? How can we decrease the waste and ensure better selection of pre-clinical models moving to clinic? Will we need phase 3 trials and what role RWE evidence will play? Will synthetic comparators give answers clinical practice needs? How can we overcome current incentives in the oncology market and stop over-production of expensive me-toos? In conversation with Marty Tenenbaum, Julian Adams, Ian Tannock and Jonathan Kimmelman.

🔍 Discover the Dynamics of the #BrainCancerMarket! DelveInsight Business Research LLP's latest report on the Brain Cancer Market offers in-depth insights into the market size, evolving therapeutic landscape, and key players driving innovation. Gain a comprehensive understanding of the current trends, unmet needs, and future opportunities shaping this critical healthcare domain. The leading #BrainCancerCompanies such as Genentech, Merck Group, Orbus Therapeutics, Inc., VBL Therapeutics (Nasdaq:VBLT), Bayer, MedImmune, DNAtrix, ONCOCEUTICS, INC., Karyopharm Therapeutics Inc., ZioPharm-Med, Novartis and others. 🌐 Stay ahead in the fight against #braincancer! Explore the Report Now @ https://lnkd.in/dKu3BrGr #BrainCancer #HealthcareResearch #MarketInsights #DelveInsight #PharmaMarket #CancerTreatment #OncologyInnovation

Wondering why you should join the Covalent Drug Discovery & Development Summit alongside 100 of your peers this December? Let "covalent" spell it out for you... Download the agenda (https://ter.li/2a8fuf) to see how this meeting will allow you and your colleagues to: ⭐ Celebrate the latest covalent strides in oncology, immunology and beyond from discovery to the clinic ⭐ Optimize covalent warheads targeting cysteine, lysine, histidine and tyrosine residues ⭐ Visualize the future funding and partnership prospects fuelling the covalency renaissance ⭐ Accelerate and de-risk your efforts to develop covalent inhibitors, PROTACs, molecular glues and biologics ⭐ Level up your covalent platform with data on the latest high-throughput, unbiased and selective screening technologies ⭐ Enrich your pipelines with optimized mass spectrometry and proteomics workflows ⭐ Network with the entire covalent community and kickstart relationships with 35+ companies already set to attend ⭐ Time to shed the spotlight on your own work with our poster session! Curious about the speaker line-up and their presentation details? Check out the program here: https://ter.li/2a8fuf #Covalent #SmallMolecule #DrugDiscovery #DrugDevelopment #Covalency

🔬 Explore the Latest in Anti-Cancer Drug Discovery with Recent Patents! 🔬 📖 Recent Patents on Anti-Cancer Drug Discovery (Volume 19, Issue 5, 2024) is your go-to resource for cutting-edge research and reviews in the field. With an Impact Factor of 2.5, this journal is indexed in Scopus, SCI Expanded, and MEDLINE/PubMed. 🌟 Aims & Scope: • Research Focus: Publishes review and research articles on patents, their applications, and comparative studies in anti-cancer drug discovery. • Thematic Issues: Features guest-edited issues on novel bioactive compounds, drug targets, and efficacy biomarkers. • Additional Content: Includes book reviews and recent important patents relevant to the field. 💡 Why It Matters: Stay updated with the latest advancements and patents in anti-cancer drug research. Essential reading for researchers and professionals involved in drug design and discovery. Discover More: Dive into our latest issue and stay ahead in the fight against cancer. #CancerResearch #DrugDiscovery #AntiCancer #Pharmacology #BiomedicalResearch #PatentReview #Oncology #Pharmacy 🔗 Read More: https://bit.ly/4g7yyM4

📣We are delighted to announce a strategic collaboration with CTI Clinical Trial and Consulting Services, a renowned full-spectrum research services provider, to bolster oncology-focused consulting services. This partnership combines decades of expertise from both organizations in oncology drug discovery and development, leveraging Crown Bioscience’s preclinical and translational models and CTI’s well-established track record in the clinical and regulatory space. Customers will benefit from the combined expert guidance, supporting the transition of oncology compounds from discovery through early-phase global trials more rapidly and effectively. This alliance aims to determine the best and most expeditious path to the clinic, ensure long-term drug development success and growth, and accelerate the delivery of more oncology therapeutics to patients. Read the full release here ➡️https://hubs.la/Q02M2QsT0 #Biotech #Bioscience #Oncology #DrugDevelopment

Want to know what’s been happening here at BiVictriX? Our annual report is now live on our website, including a Q&A with our chair, Michael Kauffman. https://lnkd.in/eNG6z2vJ 📈 2023 was a transformative year for us. Here are some of the key highlights: 🌟 BVX001 progress: We made significant strides with our lead candidate, BVX001, an anti-CD33/CD7 antibody-drug conjugate for acute myeloid leukaemia (AML). 🌟 Strengthened IP portfolio: We secured new patents across multiple territories, bolstering our intellectual property position. 🌟 FDA milestones: We had a positive INTERACT meeting with the FDA, aligning on our IND application for BVX001, which also received Orphan Drug Designation in early 2024. 🌟 BVX002 advances: Supported by strong data, we selected a preclinical lead for our second programme, BVX002, targeting ovarian cancer. 🌟 Bi-Cygni® expansion: Our Bi-Cygni® discovery platform now covers ten additional tumour types, with plans to bring two Bi-Cygni® ADCs to the clinic by 2026. 🌟 Leadership and Advisory Growth: We welcomed Dr Michael Kauffman as Non-Executive Chairman, Adrian Howd as CFO and CBO, and expanded our advisory network with Eric Rowinsky and Tami Rashal joining us as experts in solid tumours and haematology. Discover all the details and more in our full annual report:  https://lnkd.in/eNG6z2vJ #BiVictriX #AnnualReport #BVX001 #BiCygni #CancerResearch #Pharma #Biotech #Leadership #Innovation #AML #OvarianCancer #FDA #ClinicalTrials #OrphanDrugDesignation